Preexposure Prophylaxis and HIV: 2023 U.S. Preventive Services Task Force Recommendation Statement

Target Audience: Primary care clinicians for adults and adolescents, infectious disease physicians, obstetricians and gynecologists, pharmacists, sexual health clinicians, and others who prescribe PrEP

Background

In 2019, the USPSTF recommended tenofovir disoproxil fumarate/emtricitabine for preexposure prophylaxis in those at risk for HIV acquisition. Additional agents have since been approved for this indication, necessitating a reexamination of the evidence and an updated recommendation.

Key Recommendations and Updates

• Adults and adolescents who weigh ≥35 kg and are at risk for HIV acquisition should be prescribed PrEP to lower that risk because all approved agents have…